Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis

Review (35 studies n= 6686 with COVID-19) reported pooled prevalence of 4% for digestive system comorbidities, 15% for digestive symptoms, with nausea or vomiting, diarrhoea, and loss of appetite being three most common symptoms, and 19% for abnormal liver functions.

SPS commentary:

Subgroup analysis demonstrated that patients with severe COVID-19 had higher rates of gastrointestinal symptoms (OR 1.60 [95% CI 1.09–2.36; p=0.0020) and liver injury (2.20; 1.60–3.02; p<0·00001) versus those with non-severe disease.

Lancet Gastroenterology and Hepatology